240 related articles for article (PubMed ID: 29563500)
1. nc886 is induced by TGF-β and suppresses the microRNA pathway in ovarian cancer.
Ahn JH; Lee HS; Lee JS; Lee YS; Park JL; Kim SY; Hwang JA; Kunkeaw N; Jung SY; Kim TJ; Lee KS; Jeon SH; Lee I; Johnson BH; Choi JH; Lee YS
Nat Commun; 2018 Mar; 9(1):1166. PubMed ID: 29563500
[TBL] [Abstract][Full Text] [Related]
2. Autophagic degradation of SQSTM1 inhibits ovarian cancer motility by decreasing DICER1 and AGO2 to induce MIRLET7A-3P.
Liao CC; Ho MY; Liang SM; Liang CM
Autophagy; 2018; 14(12):2065-2082. PubMed ID: 30081720
[TBL] [Abstract][Full Text] [Related]
3. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.
Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S
Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511
[TBL] [Abstract][Full Text] [Related]
4. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.
Yang D; Sun Y; Hu L; Zheng H; Ji P; Pecot CV; Zhao Y; Reynolds S; Cheng H; Rupaimoole R; Cogdell D; Nykter M; Broaddus R; Rodriguez-Aguayo C; Lopez-Berestein G; Liu J; Shmulevich I; Sood AK; Chen K; Zhang W
Cancer Cell; 2013 Feb; 23(2):186-99. PubMed ID: 23410973
[TBL] [Abstract][Full Text] [Related]
5. Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
Yang Z; Jin P; Xu S; Zhang T; Yang X; Li X; Wei X; Sun C; Chen G; Ma D; Gao Q
Cancer Lett; 2018 Feb; 415():20-29. PubMed ID: 29199004
[TBL] [Abstract][Full Text] [Related]
6. A Regulatory Noncoding RNA, nc886, Suppresses Esophageal Cancer by Inhibiting the AKT Pathway and Cell Cycle Progression.
Im WR; Lee HS; Lee YS; Lee JS; Jang HJ; Kim SY; Park JL; Lee Y; Kim MS; Lee JM; Kim IH; Jeon SH; Lee YS
Cells; 2020 Mar; 9(4):. PubMed ID: 32225025
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
[TBL] [Abstract][Full Text] [Related]
8. miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-β/Smad4 signaling pathway.
Zhou J; Zhang C; Zhou B; Jiang D
Int J Mol Med; 2019 Apr; 43(4):1734-1746. PubMed ID: 30720057
[TBL] [Abstract][Full Text] [Related]
9. β-catenin downregulates Dicer to promote ovarian cancer metastasis.
To SKY; Mak ASC; Eva Fung YM; Che CM; Li SS; Deng W; Ru B; Zhang J; Wong AST
Oncogene; 2017 Oct; 36(43):5927-5938. PubMed ID: 28650464
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
Berkel C; Cacan E
Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of dicer expression in ovarian cancer tissues.
Pampalakis G; Diamandis EP; Katsaros D; Sotiropoulou G
Clin Biochem; 2010 Feb; 43(3):324-7. PubMed ID: 19782670
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer.
Wilczyński M; Żytko E; Danielska J; Szymańska B; Dzieniecka M; Nowak M; Malinowski J; Owczarek D; Wilczyński JR
Arch Gynecol Obstet; 2018 Mar; 297(3):741-748. PubMed ID: 29335784
[TBL] [Abstract][Full Text] [Related]
13. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
14. miR-17∼92 family clusters control iNKT cell ontogenesis via modulation of TGF-β signaling.
Fedeli M; Riba M; Garcia Manteiga JM; Tian L; Viganò V; Rossetti G; Pagani M; Xiao C; Liston A; Stupka E; Cittaro D; Abrignani S; Provero P; Dellabona P; Casorati G
Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8286-E8295. PubMed ID: 27930306
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.
Faggad A; Budczies J; Tchernitsa O; Darb-Esfahani S; Sehouli J; Müller BM; Wirtz R; Chekerov R; Weichert W; Sinn B; Mucha C; Elwali NE; Schäfer R; Dietel M; Denkert C
J Pathol; 2010 Feb; 220(3):382-91. PubMed ID: 19960504
[TBL] [Abstract][Full Text] [Related]
16. Characterization of microRNA expression in serous ovarian carcinoma.
Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
[TBL] [Abstract][Full Text] [Related]
17. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
Yeung TL; Sheng J; Leung CS; Li F; Kim J; Ho SY; Matzuk MM; Lu KH; Wong STC; Mok SC
J Natl Cancer Inst; 2019 Mar; 111(3):272-282. PubMed ID: 29860390
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA in cancer prognosis.
Slack FJ; Weidhaas JB
N Engl J Med; 2008 Dec; 359(25):2720-2. PubMed ID: 19092157
[No Abstract] [Full Text] [Related]
19. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
Fort RS; Mathó C; Geraldo MV; Ottati MC; Yamashita AS; Saito KC; Leite KRM; Méndez M; Maedo N; Méndez L; Garat B; Kimura ET; Sotelo-Silveira JR; Duhagon MA
BMC Cancer; 2018 Feb; 18(1):127. PubMed ID: 29394925
[TBL] [Abstract][Full Text] [Related]
20. Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression.
Di Ruocco F; Basso V; Rivoire M; Mehlen P; Ambati J; De Falco S; Tarallo V
Oncogene; 2018 Feb; 37(5):627-637. PubMed ID: 28991230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
